StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

Amgen operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Amgen's operating income for the twelve months ending Sep 30, 2026 was $12.61B, up 45.4% year over year. For fiscal 2025 it was $9.08B, up 25.1% from the year before. Over ten years it grew 0.7% a year on average. The highest annual figure on record is $10.26B in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.08B+25.1%
FY2024Dec 31, 2024$7.26B-8.1%
FY2023Dec 31, 2023$7.90B-17.4%
FY2022Dec 31, 2022$9.57B+25.2%
FY2021Dec 31, 2021$7.64B-16.4%
FY2020Dec 31, 2020$9.14B-5.5%
FY2019Dec 31, 2019$9.67B-5.7%
FY2018Dec 31, 2018$10.26B+2.9%
FY2017Dec 31, 2017$9.97B+1.8%
FY2016Dec 31, 2016$9.79B+15.6%
FY2015Dec 31, 2015$8.47B+36.8%
FY2014Dec 31, 2014$6.19B+5.5%
FY2013Dec 31, 2013$5.87B+5.2%
FY2012Dec 31, 2012$5.58B+29.3%
FY2011Dec 31, 2011$4.31B-22.2%
FY2010Dec 31, 2010$5.55B+0.7%
FY2009Dec 31, 2009$5.51B+5.6%
FY2008Dec 31, 2008$5.21B+31.0%
FY2007Dec 31, 2007$3.98B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.71B+46.9%
Q2 FY2026Jun 30, 2026$3.51B+32.3%
Q1 FY2026Mar 31, 2026$2.67B+126.3%
Q4 FY2025Dec 31, 2025$2.72B+17.7%
Q3 FY2025Sep 30, 2025$2.53B+23.4%
Q2 FY2025Jun 30, 2025$2.66B+39.1%
Q1 FY2025Mar 31, 2025$1.18B+18.9%
Q4 FY2024Dec 31, 2024$2.31B+81.8%
Q3 FY2024Sep 30, 2024$2.05B+1.3%
Q2 FY2024Jun 30, 2024$1.91B-28.9%
Q1 FY2024Mar 31, 2024$991.00M-48.4%
Q4 FY2023Dec 31, 2023$1.27B-43.0%
Q3 FY2023Sep 30, 2023$2.02B-24.0%
Q2 FY2023Jun 30, 2023$2.68B+23.3%
Q1 FY2023Mar 31, 2023$1.92B-23.2%
Q4 FY2022Dec 31, 2022$2.23B-3.2%
Q3 FY2022Sep 30, 2022$2.66B+24.9%
Q2 FY2022Jun 30, 2022$2.18B+8.4%
Q1 FY2022Mar 31, 2022$2.50B+1.9%
Q4 FY2021Dec 31, 2021$2.30B-0.8%
Q1 FY2021Mar 31, 2021$2.13B-9.6%
Q4 FY2020Dec 31, 2020$2.01B-25.0%
Q3 FY2020Sep 30, 2020$2.45B-0.8%
Q2 FY2020Jun 30, 2020$2.32B-2.5%
Q1 FY2020Mar 31, 2020$2.36B+1.4%
Q2 FY2019Jun 30, 2019$2.68B-5.4%
Q1 FY2019Mar 31, 2019$2.47B-9.3%
Q4 FY2018Dec 31, 2018$2.38B+6.1%
Q3 FY2018Sep 30, 2018$2.32B-4.8%
Q2 FY2018Jun 30, 2018$2.83B+5.0%
Q1 FY2018Mar 31, 2018$2.73B+5.2%
Q4 FY2017Dec 31, 2017$2.25B-9.7%
Q3 FY2017Sep 30, 2017$2.44B-3.5%
Q2 FY2017Jun 30, 2017$2.70B+13.4%
Q1 FY2017Mar 31, 2017$2.59B–
Q4 FY2016Dec 31, 2016$2.49B–
Q3 FY2016Sep 30, 2016$2.53B–
Q2 FY2016Jun 30, 2016$2.38B–

More Amgen figures

See a number that looks wrong?